Eli Lilly’s Weight-Loss Boom Is Rewriting Big Pharma

Eli Lilly raised its full-year outlook after strong demand for its diabetes and obesity treatments drove a major jump in revenue and profit. In this episode, we look at how GLP-1 drugs have become one of the most important growth engines in health care—and why the competition to own this market is only getting fiercer. The bigger story is what happens when one product category grows so fast that it reshapes an entire company’s strategy, valuation, and future. Support the Show • Amazon picks: https://amzn.to/4fUGHEm • Amazon picks: https://amzn.to/4pUHt8Q • Amazon picks: https://amzn.to/45a4MC9 • Need a website or app? https://hireawebteam.com • Support us on Patreon: https://www.patreon.com/c/StageZeroNews?view_as=patron&vanity=StageZeroNews • Subscribe on Supercast: https://clubelon.supercast.com/ Disclosure: Amazon links may earn a commission from qualifying purchases.